Overview
- Multiple outlets reported that the companies held initial merger talks that would value a combined group at roughly $400 billion, with reports first emerging late on Sunday and amplified on Monday.
- Markets reacted sharply when the news broke, with AstraZeneca shares falling more than 6 percent and Bristol Myers Squibb shares rising in early trading, wiping billions off AstraZeneca’s market value.
- Analysts say the talks appear driven by Bristol Myers’s exposure to upcoming patent expiries on key drugs such as Opdivo and Eliquis and by AstraZeneca’s push to expand in the U.S.
- Regulatory obstacles are a major barrier because both firms have large, overlapping oncology portfolios, making intensive review by the U.S. Federal Trade Commission and other authorities likely.
- Neither company has confirmed active negotiations, and commentators warn the deal could prompt major asset sales, political scrutiny in the U.K. and U.S., and wider shifts in where drugmakers base research and jobs.